AIRZ-FF (glycopyrrolate/formoterol fumarate/fluticasone propionate) / Glenmark - LARVOL DELTA

Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study. (PubMed, BMJ) - "Budesonide-glycopyrrolate-formoterol was not associated with improved clinical outcomes compared with fluticasone-umeclidinium-vilanterol. Given the added climate impact of metered dose inhalers, health systems seeking to decrease use of these products may consider steps to promote further prescribing of fluticasone-umeclidinium-vilanterol compared with budesonide-glycopyrrolate-formoterol in people with COPD."

Clinical • HEOR • Journal • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

Therapeutic Response to Single-Inhaler Triple Therapies in Moderate-to-Severe COPD. (PubMed, Respir Care) - "Our results showed that SITT significantly improved the IC, %IC, FVC, and %FEV when compared to pre-intervention and that F/U/V was more effective in subjects with severe symptoms, whereas B/G/F was more effective in subjects with mild symptoms."

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Expanded table: Correct use of inhalers for asthma. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Asthma • Immunology • Respiratory Diseases

Glenmark introduces 3-in-1 inhaler therapy for COPD in India, promising reduction in risk of severe attacks and improvement in lung function (Glenmark Press Release) - "Glenmark Pharmaceuticals Ltd....today announced the launch of a Single Inhaler Triple Therapy AIRZ-FF - a combination of two bronchodilators, Glycopyrronium & Formoterol and the inhalation corticosteroid Fluticasone propionate, for Chronic Obstructive Pulmonary Disease (COPD)."

Launch non-US • Chronic Obstructive Pulmonary Disease • Pulmonary Disease • Respiratory Diseases